Gohar Manzar

Aug 22, 2024 | digitalcommons.library.tmc.edu | Alexander Biederstädt |Gohar Manzar |May Daher |Gohar Shahwar

The advent of cellular immunotherapy in the clinic has entirely redrawn the treatment landscape for a growing number of human cancers. Genetically reprogrammed immune cells, including chimeric antigen receptor (CAR)-modified immune effector cells as well as T cell receptor (TCR) therapy, have demonstrated remarkable responses across different hard-to-treat patient populations.